



Natco settles patent row with Celgene

New Delhi: Natco Pharma and its US partner Allergan have settled a pending litigation with biopharma firm Celgene regarding generic Lenalidomide capsules used for treatment of multiple myeloma. "Celgene has agreed to provide Natco with a license to Celgene's patents required to manufacture and sell an unlimited quantity of generic Lenalidomide in the United States beginning January 31, 2026", Natco Pharma said in a filing to BSE. In addition, Natco will receive a volume-limited license to sell generic Lenalidomide in the United States commencing in March 2022, it said. — PTI

Patent